Clinical Trials Browser

Klatskin Tumor × tislelizumab × 90 days × Clear all

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor